Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
You may also be interested in...
UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.
AC Immune’s CEO tells Scrip that treating earlier, targeting Tau, and focusing on more homogeneous populations will be needed to successfully fight Alzheimer’s Disease.
Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.